Ethan Ennals, a 30-year-old living with axial spondyloarthritis, faces a medical crossroads after his GP advised him to stop taking nortriptyline. While the inexpensive medication significantly reduced his chronic hip and back pain, new research suggests a link between tricyclic antidepressants and increased risks of dementia and cardiovascular issues.
The 2.5 million UK patients caught in a tricyclic crossroads
Tricyclic antidepressants, including nortriptyline, amitriptyline, and desipramine, have seen a significant surge in use within the NHS. Originally developed to treat depression during the 1970s and 1980s, these drugs were later discovered to be highly effective at managing various forms of chronic pain. As reported by the source, more than 2.5 million people in the UK now rely on these medications to manage conditions ranging from migraines to inflammatory bowel disease.
Chronic pain remains one of the most difficult medical challenges to treat, affecting roughly one in three adults and half of all individuals over the age of 65. Because effective pharmaceutical options are often limited, these older tricyclic drugs have become a cornerstone of pain management for millions of patients across the country.
How axial spondyloarthritis led Ethan Ennals to a 10p miracle
For Ethan Ennals, the medication was a transformative turning point in his battle with axial spondyloarthritis. After struggling with debilitating back and hip pain that impacted his ability to swim, run, and work, Ennals found relief through a combination of adalimumab—an immune-suppressing injection costing £750 per dose—and nortriptyline. According to the report, the nortriptyline reduced his pain by 30 to 40 percent, allowing him to return to physical exercise and improve his overall quality of life.
The journey to relief was not without its hurdles. Ennals initially attempted to use amitriptyline, but found it caused excessive drowsiness. Switching to nortriptyline provided the necessary pain management with fewer sedative effects, though he noted side effects such as terrible dry mouth. Despite these minor issues, the medication allowed him to regain his health and happiness after years of physical agony.
The mounting evidence linking tricyclics to dementia and strokes
The medical benefits of nortriptyline are now being weighed against significant long-term health concerns that have emerged in recent research. There is mounting evidence suggesting that long-term use of tricyclic drugs may markedly increase the risk of developing dementia. This neurological concern is compounded by other physiological risks associated with the medication class.
The source notes that these drugs can also lead to increased blood pressure and trigger weight gain.. These side effects create a dangerous secondary effect, as they make heart attacks and strokes more likely for long-term users. For patients like Ennals, the decision to continue a life-changing medication now involves a complex calculation of immediate functional survival versus long-term neurological and cardiovascular health.
The unanswered question of whether quitting could actually increase dementia risk
The decision to cease medication is not a simple one for patients, as several critical questions regarding the long-term outcomes remain unresolved. While Ennals' GP recommended stopping the drug to mitigate dementia risks, some medical experts suggest a more complex reality. Specifically, there are claims that quitting tricyclics could, counter-intuitively, further increase a patient's risk of dementia.
It remains unclear how the medical community should prioritize these competing risks: the immediate,life-altering agony of chronic pain versus the potential for future cognitive decline. Furthermore, because the source presents a personal account, it remains to be seen how the broader population of 2.5 million users will be advised to navigate this trade-off as more data becomes available.
Comments 0